DermTech
OverviewSuggest Edit
DermTech is a diagnostics company developing and marketing non-invasive gene expression tests. It aims to provide aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. The company provides an alternative to surgical biopsy and analyzes skin biopsy samples collected non-invasively using an adhesive patch.
| Type | Private | |
| Founded | 1996 | |
| HQ | San Diego, CA, US | Map |
| Website | dermtech.com |
Recent NewsAll News
- DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
- DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry
- WKYC: Lydia Parker, M.D. – A New Way to Test for Skin Cancer
- DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines
Key People/Management at DermTech
Gary Jacobs
Director
Kevin Sun
Chief Financial Officer
Todd Wood
Chief Commercial Officer
Zuxu Yao
Chief Technical Officer
Claudia Ibarra
Chief Operating Officer
Burkhard Jansen
Chief Medical Officer
DermTech Office Locations
DermTech has an office in San Diego
San Diego, CA, US (HQ)
9404 Genesee Ave # 100, La Jolla
DermTech Financials and Metrics
Summary Metrics
Founding Date | 1996 |
DermTech total Funding | $5.6 m |
DermTech latest funding size | $5.60 m |
Time since last funding | 7 years ago |
DermTech's latest funding round in August 2013 was reported to be $5.6 m. In total, DermTech has raised $5.6 m
DermTech Revenue
| USD | |
|---|---|
Revenue (Q2, 2020) | 844.0k |
Gross profit (Q2, 2020) | (601.0k) |
Gross profit margin (Q2, 2020), % | (71.2%) |
Net income (Q2, 2020) | (9.4m) |
EBIT (Q2, 2020) | (9.4m) |
Cash (30-Jun-2020) | 61.1m |
Annual
Annual
Annual
| USD | Q1, 2018 |
|---|---|
Financial Leverage | 29.2 x |
DermTech Cybersecurity Score
DermTech Online and Social Media Presence
694 Twitter followers
DermTech has 694 Twitter Followers. The number of followers has increased 12.4% month over month and increased 18.1% quarter over quarter
DermTech's Trends
Twitter Engagement Stats for @DermTech
899
Tweets
922
Following
694
Followers
19
Tweets last 30 days
2.8
Avg. likes per Tweet
89.5%
Tweets with engagement
DermTech Blogs
January 19, 2021
DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
Content Import
Tue, 01/19/2021 - 16:31
DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
January 19, 2021 at 4:30 PM EST
This release is a…
January 14, 2021
DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry
LA JOLLA, Calif. --(BUSINESS WIRE)--Jan. 14, 2021-- DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published the results of a large registry study finding that the evaluation of genomic
January 13, 2021
WKYC: Lydia Parker, M.D. – A New Way to Test for Skin Cancer
Alexa Lee from WKYC talks with dermatologist Dr. Lydia Parker about The Parker Skin & Aesthetic Clinic as well as a new, easy, way to test for skin cancer.
The post WKYC: Lydia Parker, M.D. – A New Way to Test for Skin Cancer appeared first on DermTech.
January 12, 2021
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines
Content Import
Tue, 01/12/2021 - 16:02
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Canc…
January 11, 2021
DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
LA JOLLA, Calif. --(BUSINESS WIRE)--Jan. 11, 2021-- DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing of its previously announced underwritten public offering of 4,872,881 shares of its common
January 07, 2021
DermTech Announces Pricing of Public Offering of Common Stock
DermTech Announces Pricing of Public Offering of Common Stock
Content Import
Thu, 01/07/2021 - 00:01
DermTech Announces Pricing of Public Offering of Common Stock
January 7, 2021 at 12:00 AM EST
This release is a backfill from a News Wire
Genera…
DermTech Frequently Asked Questions
When was DermTech founded?
DermTech was founded in 1996.
Who are DermTech key executives?
DermTech's key executives are Gary Jacobs, Kevin Sun and Todd Wood.
How many employees does DermTech have?
DermTech has 60 employees.
Who are DermTech competitors?
Competitors of DermTech include CirculoGene, CGC Genetics and Complement Genomics.
Where is DermTech headquarters?
DermTech headquarters is located at 9404 Genesee Ave # 100, La Jolla, San Diego.
Where are DermTech offices?
DermTech has an office in San Diego.
How many offices does DermTech have?
DermTech has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies